Arkolith/Insider Trading/EDIT/Form 4

O'Neill Gilmore Neil

CEO, DirectorEditas Medicine, Inc. (EDIT) · full profile →Form 4 · filed Mar 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$733K
Net Open-Market Flow
-$733K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 5, 2024Sell(S)78K$9.42$733K327K
Mar 2, 2024Grant(A)72K—$0405K
Mar 2, 2024Grant(A)72K—$0333K
Mar 2, 2024Grant(A)131K—$0261K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2024Grant(A)392K—$0392K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001650664-24-000015) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML